Abstract
Author Summary This study investigates shared genetic influences that may contribute to the circadian rhythm disruption and sleep issues in neurodevelopmental and neuropsychiatric conditions. Using polygenic score analysis on large-scale genetic studies of autism, attention-deficit/hyperactivity disorder, schizophrenia, and bipolar disorder, we tested their ability to predict chronotype and insomnia status of participants in the UK Biobank. Our findings reveal that polygenic scores for autism, schizophrenia, and bipolar disorder are associated with an evening chronotype, while polygenic scores for attention-deficit/hyperactivity disorder, autism, schizophrenia, and bipolar disorder are associated with insomnia. Pathway analysis identified the enrichment of shared genetic variation between chronotype and bipolar disorder in the NRF2-KEAP1 and mRNA splicing minor pathways. Previous studies have linked the NRF2-KEAP1 pathway to the pathology of bipolar disorder and schizophrenia. NRF2 and splicing components have been previously reported to be rhythmically regulated by circadian clock genes. These results suggest a potential role for the NRF2-KEAP1 and mRNA splicing minor pathways in mediating circadian rhythm disturbances in bipolar disorder, providing insights into the genetic basis of sleep issues in neuropsychiatric conditions.
It has been postulated that circadian dysfunction may contribute to the sleep problems prevalent in neurodevelopmental and neuropsychiatric conditions. Genetic correlations between numerous pairs of neurodevelopmental or neuropsychiatric and sleep phenotypes have been identified. We hypothesize that this overlapping genetic variation is enriched in certain biological pathways.
We used genome-wide polygenic score analysis to confirm previously reported genetic correlations and pathway-based polygenic score analysis to identify enriched pathways. We created polygenic scores using summary statistics from the largest genome-wide association studies (GWAS) of autism (AUT), attention-deficit/hyperactivity disorder (ADHD), schizophrenia (SCZ) and bipolar disorder (BP). We tested the performance of these polygenic scores in predicting chronotype and insomnia status of UK Biobank participants. For the pathway-based polygenic scores, we restricted genetic variation to SNPs that mapped to genes within 451 pathways from the Reactome database.
Genome-wide polygenic scores for AUT, SCZ and BP were found to be associated with an evening chronotype, and polygenic scores for ADHD, AUT, SCZ and BP were found to be associated with insomnia status. Pathway-based polygenic score analysis identified the NRF2 KEAP1 and mRNA splicing minor pathways as being enriched for genetic variation overlapping between chronotype and BP. For the NRF2 KEAP1 pathway, the signal is enriched in the subset of genes that function with KEAP1 to regulate NRF2 expression. Examination of eQTL data pointed to BP associated SNPs within these gene-sets being associated with expression changes of many genes to which they map. A number of these eQTL SNPs were reported to be genome-wide significant for SCZ in previous studies.
These results demonstrate that the overlapping genetic variation between chronotype and BP is enriched in genes involved in the NRF2-KEAP1 and mRNA splicing minor pathways. Animal model and human cell line studies have previously linked the NRF2 pathway to the pathology of BP and SCZ. Additionally, NRF2 and splicing components have been reported to be rhythmically regulated by circadian clock genes. Our results suggest that these pathways could be involved in mediating the disrupted circadian rhythm phenotype of BP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 950010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank data use was approved for access under the application number 16389. UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB). This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
UK Biobank genotype and questionnaire data can be accesssed via the UK Biobank research analysis platform (RAP): https://ukbiobank.dnanexus.com/landing. The Research Analysis Platform is open to researchers who are listed as collaborators on UKB-approved access applications. All results produced in the study are available in the manuscript or supplementary tables.
